UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2025

 

Commission File Number: 001-42453

 

Park Ha Biological Technology Co., Ltd.

 

901, Building C, Phase 2

Wuxi International Life Science Innovation Campus
196 Jinghui East Road

Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000

+86 400 012 7562

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

On August 25, 2025, Mr. Da Yang tendered his resignation as an independent director of Park Ha Biological Technology Co., Ltd. (the “Company”), effective August 25, 2025. Mr. Da Yang’s resignation was not a result of any disagreement with the Company’s operations, policies or procedures.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Park Ha Biological Technology Co., Ltd.
     
Date: August 25, 2025 By: /s/ Xiaoqiu Zhang
  Name:  Xiaoqiu Zhang
  Title: Chief Executive Officer, Chairperson of the Board of Directors

 

2